title: Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.
abstract: Acute myeloid leukemia (AML) with deranged core-binding factor beta (CBFβ) is usually associated with a favorable prognosis with 50-70% of patients cured using contemporary treatments. We analyzed the prognostic significance of clinical features on 58 patients with CBFβ-AML aged ≤60 years. Increasing age was the only predictor for survival (P <0.001), with an optimal cut-point at 43 years. White blood cells (WBCs) at diagnosis emerged as an independent risk factor for relapse incidence (P = 0.017), with 1.1% increase of hazard for each 1.0 × 10(9) /L WBC increment. KIT mutations lacked prognostic value for survival and showed only a trend for relapse incidence (P = 0.069).
authors.affiliation: Division of Haematology, Niguarda Hospital, Milan, Italy; Division of Haematology, Department of Internal Medicine, Valduce Hospital, Como, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Cairoli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Beghini
authors.forename: Mauro
authors.initials: M
authors.lastname: Turrini
authors.forename: Giambattista
authors.initials: G
authors.lastname: Bertani
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Nadali
authors.forename: Francesco
authors.initials: F
authors.lastname: Rodeghiero
authors.forename: Carlo
authors.initials: C
authors.lastname: Castagnola
authors.forename: Francesca
authors.initials: F
authors.lastname: Lazzaroni
authors.forename: Michele
authors.initials: M
authors.lastname: Nichelatti
authors.forename: Felicetto
authors.initials: F
authors.lastname: Ferrara
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Enrico
authors.initials: E
authors.lastname: Pogliani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050658:Core Binding Factor beta Subunit / Q000097:blood* / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000628:therapy; D007958:Leukocyte Count; D007962:Leukocytes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000097:blood / Q000235:genetics; D012737:Sex Factors; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; C493692:CBFB protein, human; D050658:Core Binding Factor beta Subunit; D019009:Proto-Oncogene Proteins c-kit